Ispitivanje statusa gvožđa kod davalaca krvi vraćenih zbog niskog nivoa hemoglobina

  • Mirjana Kovač University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Bojana Erić University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Jelena Stojneva Istatkov University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Vojislav Lukić University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Ana Milić University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Dragana Vukičević University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Dušan Orlić University of Belgrade, Blood Transfusion Institute of Serbia, Belgrade, Serbia
  • Branko Tomić University of Belgrade, Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia
Ključne reči: krv, davaoci, hemoglobini, gvožđe, feritin, laboratorijske tehnike i procedure

Sažetak


Uvod/Cilj. Određivanje nivoa hemoglobin (Hb) je rutinski deo selekcije dobrovoljnih davalaca krvi. Prethodno publikovane studije pokazale su da se nedostatak gvožđa javlja kod redovnih davalaca krvi. Cilj ove prospektivne studije je bio da se utvrdi status gvožđa kod davalaca kod kojih je pre davanja utvrđen nizak nivo Hb i da se proceni stepen korelacije kapilarnih metoda, sa referentnom metodom određivanja Hb iz venske krvi, kao i sa i nivoom feritina. Metode. U periodu od februara 2017. do decembra 2018. godine, bilo je uključeno 200 dobrovoljnih davalaca sa niskim nivoima Hb, starosne dobi 19–64 godine (medijana 39 godina). Hb je određivan primenom metode bakar sulfat, kapilarnom metodom „HemoCue“, i iz venske krvi u sklopu određivanja kompletne krvne slike (KKS). Nivo feritina određivan je primenom turbodimetrijske metode.  Rezultati. Nizak nivo feritina utvrđen je kod 42,7% muškaraca i 57,3% žena (p = 0,008). U odnosu na nivo feritina < 12 μg/L, odnosno > 50 μg/L, zabeležena je značajna razlika između polova (= 0,023, odnosno = 0,022). Poređenje vrednosti Hb dobijenih kapilarnim metodama u odnosu na referentne vrednosti Hb, određene iz KKS, pokazalo je da metoda s bakar sulfatom daje lažno niske vrednosti Hb kod 10,5% slučajeva (p < 0,001). Vrednosti Hb dobijene metodom „HemoCue-a“ značajno su korelirale sa vrednostima Hb iz KKS, dok korelacija između nivoa feritina i Hb, određenog pomoću obe kapilarne metode, nije uočena. Zaključak. Kod 51,5% naših davalaca krvi koji su vraćeni zbog niskih vrednosti Hb utvrđen je snižen nivo feritina. Na osnovu ovih rezultata neophodno je odrediti algoritam za detekciju nedostatka gvožđa, dok je kapilarna metoda (HemoCue) pogodnija metoda za testiranje Hb pre davanja krvi.

Reference

Eder A. Evidence-based selection criteria to protect blood donors. J Clin Apher 2010; 25(6): 331‒7.

Baart AM, van den Hurk K, de Kort WL. Minimum donation in-tervals should be reconsidered to decrease low hemoglobin de-ferral in whole blood donors: an observational study. Transfu-sion 2015; 55(11): 2641–4.

Spencer BR, Johnson B, Wright DJ, Kleinman S, Glynn SA, Cable RG, et al. Potential impact on blood availability and donor iron status of changes to donor hemoglobin cutoff and inter-donation intervals. Transfusion 2016; 56(8): 1994–2004.

Goldman M, Magnussen K, Gorlin J, Lozano M, Speedy J, Keller A, et al. International Forum regarding practices related to donor

haemoglobin and iron. Vox Sang 2016; 111: 449–5.

WHO. Blood safety and availability. Available from: http://www.who.int/mediacentre /factsheets /fs279/en/ [accessed 2017June 28].

Mast AE. Low hemoglobin deferral in blood donors. Transfus Med Rev 2014; 28(1): 18‒22.

Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation induced iron depletion. Transfus Med 2008; 18(1): 13‒27.

Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, et al. Iron deficiency in blood donors: the REDS-II Do-nor Iron Status Evaluation (RISE) study. Transfusion 2012; 52(4): 702‒11.

Rigas AS, Sørensen CJ, Pedersen OB, Petersen MS, Thørner LW, Kotzé S, et al. Predictors of iron levels in 14,737 Danish blood donors: results from the Danish blood study. Transfusion 2014; 54(3 Pt 2): 789‒96.

Gorlin J. Iron man pentathlon or "we have met the enemy and they is us!" Transfusion 2014; 54(3 Pt 2): 747‒9.

Lotfi R, Wernet D, Starke U, Northoff H, Cassens U. A noninva-sive strategy for screening prospective blood donors for ane-mia. Transfusion 2005; 45(10): 1585‒92.

Vuk T, Magnussen K, De Kort W, Folléa G, Liumbruno GM, Schennach H, et al. International forum: an investigation of iron status in blood donors. Blood Transfus 2017; 15(1): 20–41.

Hillgrove T, Moore V, Doherty K, Ryan P. The impact of tempo-rary deferral due to low hemoglobin: future return, time to re-turn, and frequency of subsequent donation. Transfusion 2011; 51(3): 539–47.

Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. Transfusion 2007; 47(8): 1514–23.

Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013; 381(9880): 1866–75.

Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 316(19): 2025‒35.

Council of Europe. Guide to the Preparation, Use and Quality Assuranceof Blood Components. 19th ed. Strasbourg, France: Council of Europe; 2016.

WHO. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. (WHO/NMH/NHD/MNM/11.2). 2011. Available from: http://www.who.int /vmnis/indicators/ serum_ ferritin.pdf [accessed 2017 June 28].

Finch CA, Cook JD, Labbe RF, Culala M. Effect of blood do-nation on iron stores as evaluated by serum ferritin. Blood 1977; 50(3): 441–7.

Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. JAMA 1981; 245(20): 2038‒43.

Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev 2016; 4: CD009747.

Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. Cochrane Database Syst Rev 2014; 7: CD009532.

Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, et al. Oral iron supplementation after blood donation: a ran-domized clinical trial. JAMA 2015; 313(6): 575‒83.

Magnussen K, Ladelund S. Handling low hemoglobin and iron deficiency in a blood donor population: 2 years' experience. Transfusion 2015; 55(10): 2473‒8.

Mast AE, Bialkowski W, Bryant BJ, Wright DJ, Birch R, Kiss JE, et al. A randomized, blinded, placebo-controlled trial of edu-cation and iron supplementation for mitigation of iron defi-ciency in regular blood donors. Transfusion 2016; 56(6 Pt 2): 1588‒97.

Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spen-cer BR, et al. Effect of iron supplementation on iron stores and total body iron after whole blood donation. Transfusion 2016; 56(8): 2005–12.

Bryant BJ, Yau YY, Arceo SM, Daniel-Johnson J, Hopkins JA, Leitman SF. Iron replacement therapy in the routine manage-ment of blood donors. Transfusion 2012; 52(7): 1566–75.

Spencer B. Blood donor iron status: are we bleeding them dry? Curr Opin Hematol 2013; 20(6): 533–9.

AABB, Association Bulletin 17-02: Updated Strategies to Limit or Prevent Iron Deficiency in Blood Donors. Available from: http://www.aabb.org/resources/publications/bulletins/Pages/ab17-023.aspx [accessed 2017 March 16].

Eder A, Goldman M, Rossmann S, Waxman D, Bianco C. Selec-tion criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (he-movigilance). Transfus Med Rev 2009; 23(3): 205‒20.

Objavljeno
2021/03/18
Rubrika
Originalni članak